Quick orientationEvidence update: 6 October 2026
What is Kisspeptin-10?
Kisspeptin-10 is a short piece of kisspeptin that activates the KISS1 receptor - one of the important upstream switches controlling human reproduction.
Why people are interested
The potential benefits, unpacked.
Here are the goals and claims that bring readers to this guide. The evidence note shows which part is demonstrated, early research or still a question.
The headline interest
Small human studies have explored reproductive hormones, fertility and sexual/emotional responses.
What the mechanism suggests
KISS1R agonist upstream of GnRH, LH and FSH signalling; central to reproductive hormone control.
What still needs proving
The key question is whether the claimed benefit has been demonstrated in controlled human studies using the same compound, route and population.
What is it actually doing?
KISS1R agonist upstream of GnRH, LH and FSH signalling; central to reproductive hormone control.
The important distinction is between changing a biomarker or pathway and producing a meaningful outcome that people can feel, measure or sustain.
Results at a glanceHuman evidence
What did the studies actually find?
Human study deep dive
The most informative human evidence we could identify is translated below, with the original source linked.
Study evidenceStudy deep dives
The important studies, translated into normal English.
Each synopsis keeps the trial design, actual results and limitations together. Graphs below are redrawn from the cited numerical results so you can see the size of the effect without having to decode a journal figure.
Kisspeptin in men with HSDD — JAMA 2023
Double-blind crossover RCT · 32 completersKisspeptin-54 infusion altered sexual-processing brain activity and increased penile tumescence by up to 56% more than placebo during sexual stimuli; several behavioural desire measures also improved.
Human sexual-response biology is genuinely interesting, but the study used kisspeptin-54 infusion, not a retail Kisspeptin-10 self-use protocol.
What it doesn't prove: Small experimental study; surrogate/short-term endpoints and a different kisspeptin form.
Read the original study / source ↗
Dosing referenceResearch, licensed & reported protocols
What doses and schedules are actually documented?
Human research or licensed product information is separated from clinic and community practice. These are source-attributed reference protocols, not personalised dosing recommendations.
Human research / licensed or product dosing
| Protocol / context | Amount & frequency | Duration | Titration | Evidence |
|---|---|---|---|---|
| Healthy men IV bolus | 0.01–3 mcg/kg IV | Acute | Dose-response; maximal LH response at 1 mcg/kg in study | Human physiology |
| Healthy men infusion | 1.5 or 4 mcg/kg/hour IV | Up to 22.5 h | Continuous | Human physiology |
| Women study | IV bolus up to 10 nmol/kg; SC bolus up to 32 nmol/kg; IV infusion up to 720 pmol/kg/min | Acute | Escalating experimental doses | Human physiology |
| Hyperprolactinaemic women | 1.5 mcg/kg/hour IV infusion | 12 h | Continuous | 2-patient exploratory human study |
Community / clinic / specialist protocols
| Pattern | Amount & frequency | Cycle | Progression | Status |
|---|---|---|---|---|
| Lower intermittent | 50–100 mcg SC | Intermittent | Usually fixed | Community |
| Most recurring | 100–200 mcg SC | Daily or several times weekly | Usually fixed | Community |
| Higher experimental | 500 mcg SC | Intermittent | No validated titration | Community |
| Community calculator data | 100 mcg most common logged amount; median 200 mcg | Daily most common, then 3×/week | — | Aggregated calculator inputs |
Kisspeptin-10 has clear acute human dose-response data, but essentially no evidence validating repeated community SC schedules. Reproductive state and sex materially change response.
Evidence checked: 7 October 2026
Routes and formulations matter. A topical study does not validate injection; an IV research dose does not establish a fixed SC dose; and evidence for one molecular form must not be silently transferred to another.
Community reportsCommunity reports
What are people actually doing?
Community experience exists, but is anecdotal
Forums discuss schedules, effects and side effects, but posts are uncontrolled self-reports and product identity may be uncertain. Use them to understand what people report—not to estimate efficacy or establish a dose.
View the discussion on Reddit ↗
Safety and uncertaintySafety, side effects & what we don't know
Promising physiological research, but not a general libido or fertility treatment.
Product identity, sterility and concentration are additional uncertainties for unlicensed research products. Evidence from an approved medicine or a clinical trial should not be transferred automatically to a differently sourced product.
QuestionsQuestions worth asking
What is the strongest evidence here?
Human sexual-response biology is genuinely interesting, but the study used kisspeptin-54 infusion, not a retail Kisspeptin-10 self-use protocol.
Does a biological mechanism prove the claimed benefit?
No. Receptor activity, cell effects and animal results can justify research, but controlled human outcomes are a separate evidential step.
Is the research protocol a recommended dose?
No. The site reports study protocols to explain the evidence. It does not turn them into personalised self-use instructions.
Primary sourcesStudies, sources & further reading
External links are provided for transparency and further reading. Linking to a study, discussion or organisation does not mean Peptides Peptalk endorses every conclusion on that page.